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[‘HlAzidobutyryl clentiazem, a new photoactivatable diltiazem derivative, has a higher binding affinity than azidobutyryl diltiazem. It can be 
covalently incorporated into the a, subunit of the skeletal muscle calcium channel by UV irradiation, which allows the benzothiazepine binding 
site to be determined. The photolabeled a, subunit and its proteolytic fragments were analyzed with a panel of sequence-directed antibodies. The 
results suggest hat the linker region between segment S5 and S6 of domain IV is involved in benzothiazepine binding. This site is different from 
the dihydropyridine and verapamil binding sites. 
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1. INTRODUCTION 
Selective calcium antagonists such as 1 ,Cdihy- 
dropyridines (e.g. nifedipine), phenylalkylamines (e.g. 
verapamil) and benzothiazepines (e.g. diltiazem) inhibit 
calcium influx through voltage dependent calcium 
channels. These drugs are widely used in the treatment 
of various cardiovascular disorders. Benzothiazepines, 
in particular, are quite useful because of a low side effect 
profile [l-3]. 
It is likely that the calcium antagonist drugs exert 
their effects by binding to distinct but allosterically cou- 
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pled receptor sites of the voltage-dependent calcium 
channel [4]. These sites are part of the o+ subunit of the 
calcium channel, as shown by photoaffinity labeling 
[5-lo]. The regions participating in the formation of 
drug binding domains for phenylalkylamines and dihy- 
dropyridines have recently been identified within the 
primary structure of the skeletal muscle 01, subunit after 
photoaffinity labeling using sequence-directed antibod- 
ies and defined proteolysis. The phenylalkylamine bind- 
ing site is thought to be located at the intracellular 
surface of the membrane in the S6 segment of domain 
IV [l 11. In contrast, the dihydropyridine binding site is 
located extracellularly, near the putative channel pore 
involving transmembrane helices S6 in domain III and 
IV [12,13]. 
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verse tubular membranes; CP, calcium channel peptide; WGA, wheat- 
germ agglutinin; SDS, sodium dodecylsulfate; PAGE, polyacrylamide 
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It was shown in electrophysiological studies by using 
quarternary derivatives of diltiazem [14] and benzazep- 
ine [15], that the target of action of these compounds 
appears to be located on the extracellular portion of the 
cc, subunit. However, the exact location of the ben- 
zothiazepine binding domain within the primary struc- 
ture of the 01, subunit remains to be elucidated. Pho- 
toaffinity labeling using an appropriate benzothiazepine 
derivative should be a promising avenue for this area. 
Earlier studies have shown that radiolabeled azidobu- 
tyryl diltiazem, a photoactivable benzothiazepine-type 
compound, covalently labels the 01, subunit of the cal- 
cium channel [lo]. 
In the present study, a part of the benzothiazepine 
binding site(s) in the voltage-dependent calcium channel 
has been localized within the tl, subunit using a new 
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photoaffinity probe of a diltiazem analog. Here we de- 
scribe an analysis of the photolabeled CI, subunit before 
and after protease digestion by probing with a panel of 
sequence-directed antibodies. The results are compared 
to the known photolabeled sites for dihydropyridines 
and verapamil. 
2. MATERIALS AND METHODS 
2.1. Materials 
[3H]Azidobutyryl clentiazem ([jH]ABC, 85 Ci/mmol), ABC and 
clentiazem were gifts from Tanabe Seiyaku Co., Osaka, Japan. 
[‘H]Clentmzem (108 Ci/mmol) and diltiazem were gifts from Marion 
Merrell Dow Inc., Kansas City, MO. Lysyl endoprotease (Lys-C, 
Achromobacter protease I) was obtained from Wako Chemical Co., 
Osaka, Japan, and tosyl L-phenylalanine chloromethyl ketone-treated 
trypsin (TPCK-trypsin) (from bovme pancreas) and protein A-Sepha- 
rose 4B-CL were from Worthington and Pharmacia LKB. respec- 
tively. 
2.2. Site-directed antibodies 
Polyclonal antisera were raised in rabbits against synthetic alcium 
channel peptides corresponding to sequences of the skeletal muscle CZ, 
subunit (Fig. 1). Peptide CP-(1011~1026C), P-(GC1381-1399) or 
CP-(1401-1415CG) were synthesized by the addition of a cysteine, 
glycylcysteine, or cysteinylglycine residue to the C- or N-terminus of 
CP-(1011~1026C), CP-(1381-1399), CP-(1401-1415) respectively. 
Peptide synthesis, coupling to porcine thyroglobuhn, and antibody 
generation have been described [12]. 
2.3. Radioligand binding stud) 
ABC was characterized by competition binding with [‘Hlclentiazem 
according to the method previously described [lo]. In brief, rabbit 
skeletal muscle membranes (SM-membranes) enriched m L-type cal- 
cium channel antagonist receptors were incubated with 2 nM [‘Hlclen- 
tiazem for 60 min at 15°C in a buffer contaimng 50 mM Tris-HCI, pH 
8.0 in the absence or presence of unlabeled ABC, clentiazem or dil- 
tiazem. Membrane-bound radioactivity was determined by a rapid 
filtration method. The data were analyzed with a nonlinear least 
squares LIGAND program originally described by Munson and 
Rodbard [16]. 
2.4. PhotoafCty labeling 
Skeletal muscle membranes were homogenized and centrifuged at 
100,000 x g for 30 min, the pellets were resuspended in the buffer (50 
mM Tris-HCl. pH 8.4, containing 2 mM EGTA and four protease 
inhibitors: 0.25 mM phenylmethanesulfonyl fluoride, 1 mM iodoacet- 
amide, 1 mM leupeptine and 1 PM pepstatin A) giving 10 mg/ml 
suspension. The membranes were incubated with 50 nM [3H]ABC in 
Repeat I Repeat II 
the absence or presence of unlabeled 0.1 mM diltiazem at 25°C for 60 
min. The incubation mixture was then irradiated with UV light (Phil- 
ips 38 WiTL lamp and 100 W/lamp) on ice at a distance of 10 cm for 
20 min, and centrifuged at 100,000 x g for 40 min. The pellets were 
homogenized with the solubilization buffer (1% digitonin in 10 mM 
HEPES-Tris, pH 8.4, containing 185 mM KCI, 1.5 mM CaCl, and the 
four protease inhibitors), kept on ice for 60 min, and centrifuged at 
100,000 x g for 45 min. The supematant was irradiated again on ice 
with UV lights (Philips 38 W/TL lamp and 100 W/lamp) at a distance 
of 10 cm for 50 min. Labeled calcium channel proteins were purified 
using WGA-Sepharose 6MB [17], followed by size-exclusion chroma- 
tography with two columns of TSK G4000SW and TSK G3000SW, 
in the elution buffer (20 mM sodium phosphate, pH 7.0 containing 
0.2% SDS) at a flow rate of 0.5 ml/min. Fractions containing the 
radiolabeled a, subunit were pooled, lyophihzed and subjected to 
tryptic digestion and immunoprecipitation. 
2.5. Protease digestion ofpurified [-‘H]azidobutyryl clentiazem-labeled 
CL, subunit 
For Lys-C digestion, the lyophilized [3H]ABC-labeled al subunit 
(90,000 dpm) was dissolved in water (2 ml) and the solution was 
dialyzed against 6M urea and subsequently against 0.003% Triton 
X-100 in 10 mM Tris-HC1 (pH 7.5). The dialyzed sample was concen- 
trated to 0.3 ml by lyophilization and the concentrate was digested 
with Lys-C (4 mg/ml) in 0.1 M Tris-HCl (pH 9.0) for 12 h at 37°C. 
For trypsin digestion, the lyophilized [3H]ABC-labeled a, subunit was 
dissolved in 0.4 M Tris-HCl. pH 8.0 and reduced with 1% 2-mercap- 
toethanol, followed by carboxymethylation with sodium iodoacetate 
as previously described [121. The sample was dialyzed against 6 M urea 
and subsequently against 0.003% Triton X-100 in 10 mM Tris-HC1 
(pH 7.5). The dialyzed sample was concentrated to 0.3 ml by lyophil- 
ization and the concentrate was digested with trypsin (6.25 pg/ml) in 
0.1 M Tris-HCl (pH 8.2) containing 2 mM CaCI, at 37°C. After 12 
h, trypsin (6.25 &ml) was added and the digestion continued for 12 
more hours. The digestion was terminated by the addition of diisopro- 
pyl phosphofluoridate to a final concentration of 5 mM. 
2.6. Immunopreclpitation 
Immunoprecipitation was carried out essentially as described [12]. 
Briefly, either digested or non-digested [‘H]ABC-labeled a, was incu- 
bated with antibody-coupled protein A-Sepharose 4B-CL gel (100 ~1) 
in RIA buffer (10 mM Tris-HCl, pH 7.2 containing 150 mM NaCl and 
0.3% Triton X-100) at room temperature. After 2 h, the gel was 
washed with RIA buffer. Immunoprecipitated radioactivity was either 
directly determined by liquid scintillation counting after resuspension 
of the gel in 0.1 M sodium citrate (pH 3.0) or analyzed by SDS-PAGE 
after extraction with hot 1% SDS. 
2.7. SDS-PAGE 
The intact a, subunit was analyzed on SDS-PAGE using 7% poly- 
acrylamide gels according to Laemmli [18]. For separation of the 
Repeat III Repeat IV 
Fig. 1. 
- COOH 
Location of specific sequences on the a, of the rabbit skeletal muscle calcium channel. Antibodies were raised by synthetic 
corresponding to the amino acid residues of 101 l-1026 (P7), 133881351 (Pl), 1381-1399 (P9) and 1401-1415 (PO). 
peptides 
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digested fragments, he gel system described bySchaegger and von 
Jagow [19] was used. Detection of labeled peptides by gel slicing was 
carried out as described [12]. 
3. RESULTS AND DISCUSSION 
In competition binding studies, ABC, like clentiazem 
and diltiazem, completely inhibited specific binding of 
[3H]clentiazem to the skeletal muscle membranes (Fig. 
2). The equilibrium dissociation constants (Kd values) 
for ABC, clentiazem, and diltiazem were 60 + 5,44 ? 6, 
and 148 ? 12 nM, respectively, and the Hill slopes for 
these compounds were close to unity, viz., 0.99 + 0.08, 
1 .Ol + 0.16, and 1.14 ? 0.2, respectively. These data in- 
dicate that ABC is a competitive inhibitor with a rela- 
tively high affinity for the diltiazem receptor site of the 
skeletal muscle calcium channel. 
By photoirradiation, [3H]ABC was covalently incor- 
porated into the 170 kDa polypeptide, the a, subunit of 
the calcium channel from rabbit skeletal muscle (Fig. 3). 
Specific incorporation was also demonstrated by an- 
other experiment in which the photo-incorporation was 
blocked in the presence of an excess amount of dil- 
tiazem, the prototypical and reversible benzothiazepine 
ligand for this receptor (Fig. 3). Efficient photolabeling 
was achieved by a two-step UV irradiation protocol 
which includes (1) irradiation of the membrane after 1 
h incubation with [3H]ABC and (2) a second longer 
irradiation after removing free ligand and solubilizing 
with 1% digitonin. 
The photolabeled samples were purified by affinity 
chromatography with WGA-Sepharose 6MB followed 
by size-exclusion chromatography to yield the 
[3H]ABC-labeled CI, subunit as a major component. Par- 
tially purified labeled samples were digested with prote- 
olytic enzymes (either Lys-C or trypsin). The cleavage 
mixture was then assayed with sequence-directed anti- 
bodies in order to identify those specific segments of a, 
where the radiolabeled ligand covalently binds. Fig. 4 
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Fig. 2. Inhibition of specific [3H]clentiazem binding by diltiazem-type 
ligands. SM-membranes were incubated with 2 nM [3H]clentiazem in 
the presence of indicated concentrations of unlabeled clentiazem (o), 
ABC (o), or diltiazem (A). 
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Fig. 3. Specific photoaffinity labeling of the diltiazem receptors with 
[‘H]ABC. The SM-membranes were incubated with 50 nM rH]ABC 
(open circles), or 50 nM [‘H]ABC plus 0.1 mM diltiazem (filled 
squares). Calcium channel proteins were purified by WGA-Sepharose, 
treated with 50 mM NEM, and electrophoresed. The radioactivity was 
determined in 3 mm gel slices. M, standards are shown. 
shows the immunoprecipitation profile of non-digested 
(dotted bars), Lys-C digested (solid bars), and trypsin- 
digested (open bars) photoaffinity labeled a, subunit by 
several sequence-directed antibodies (see Fig. 1). The 
non-digested a, subunit was immunoprecipitated by all 
the antibodies. After digestion with Lys-C, anti-CP- 
(1338-1351) and anti-CP-(GC1381-1399). The antibod- 
ies were still able to bind radioactivity (15% and 18% 
of the specifically bound radioactivity associated with 
a,, respectively). Contrary to the Lys-C digestion, none 
of the antibodies immunoprecipitated any labeled frag- 
ment after tryptic digestion. This is in clear contrast to 
previous observations that anti-CP-(101 l-1026C) and 
anti-CP-(1338-1351) [12], or anti-CP-(1339-1354) and 
anti-CP-( 1382-l 400) [ 131 efficiently immunoprecipi- 
tated the tryptic fragments of the 01~ subunit that were 
labeled by photoactivable dihydropyridines such as di- 
azipine [12], azidopine and PN200-110 [ 131, or by N- 
methyl-LU49888, a photoactivable verapamil [l 11, re- 
spectively. These results suggest hat the region photola- 
beled by [3H]ABC is at a site distinct from dihy- 
dropyridines and verapamil. 
Lys-C digestion of the photolabeled and purified 
sample generated several fragments of 25-50 kDa, 16 
kDa, and 12 kDa as major fragments with minor frac- 
tions of 8 kDa, 4-5 kDa, and 2-3 kDa (Fig. 5). We 
found two major immunoprecipitated fragments of 12 
kDa and 25 kDa by anti-CP-( 1338-l 351) antibody and 
anti-CP-(GCI 381-1399) antibody but not by anti-CP- 
(1401-1415CG) antibody. However, after tryptic diges- 
tion no photolabeled fragment was detected by any of 
the three antibodies described above. It is predicted 
from the primary amino acid sequence of the a, subunit 
that Lys-C should give a 7.4 kDa polypeptide of amino 
acid (a.a.) 1337-1403 which includes the recognition 
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Fig. 4. Immunoprecipitation of the [‘H]ABC-labeled a, subunit by 
various sequence-directed antibodies before and after protease diges- 
tion. Photolabeled a, subunit (open bars) and its digests with Lys-C 
(4 mg/ml; solid bars) or with trypsin (12.5 pg/ml; shaded bars) were 
immunoprecipitated with the antibodies against the CP indicated. 
sites for the two antibodies described above. Thus the 
12 kDa and 25 kDa fragments are probably the two 
partially digested fra~ents including the 7.4 kDa pol- 
ypeptide. Together with the observation that the anti- 
CP-( 140 1 - 14 1 XC) antibody did not immunoprecipi- 
tate these fragments, the fragments containing the 7.4 
kDa polypeptide and the additional residues extend to- 
wards the N-terminal end of CI, subunit. The corre- 
sponding amino acids are considered as a.a. 129221403 
and a.a. 1173-1403 for 12 kDa and 25 kDa fragment, 
respectively. 
No antibodies immunoprecipitated any labeled frag- 
ments after tryptic digestion which can generate 6.2 
kDa (a.a. 1337-1389) or 7.4 kDa (a.a. 1337-1403), as 
demonstrate previously [I 23, from the fragments of 12 
kDa and 25 kDa. Therefore, the photolabeled site with 
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Fig. 5. Analysis of immunoprecipitated [SH]ABC-labeled fragments 
from Lys-C digestion by SDS-PAGE. ABC-labeled a, was digested 
with Lys-C (4 /*g/ml). Aliquots of the digest were separated by SDS- 
PAGE (open circles) or after immunoprecipitation with anti-CP- 
(GC1381-1399) (filled squares) in the gel system described by 
Schaegger and von Jagow [19]. 
f3H]ABC is located between a.a. 1292 and 1403 exclud- 
ing a.a. 1337-1403. It is likely that the 25 kDa fragment 
is a precursor of the 12 kDa fragment and both of the 
fragments have the same labeled site with t3H]ABC, but 
further work is necessary for proof. 
This is the first demonstration by photoaffinity label- 
ing that the binding site for the diltiazem-type calcium 
antagonist is in domain IV, but at a site different from 
dihydropyridines and phenylalkylamines [l l-1 31. Addi- 
tional studies are required in order to identify the exact 
binding sites for diltiazem-ty~ antagonists. ABC has 
proven to be a promising candidate for probing specific 
regions. 
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